Suppr超能文献

基于机制的非阿片类镇痛靶点。

Mechanism-based nonopioid analgesic targets.

作者信息

Zeng Xiangsunze, Powell Rasheen, Woolf Clifford J

出版信息

J Clin Invest. 2025 Jun 2;135(11). doi: 10.1172/JCI191346.

Abstract

Acute pain management has historically been dominated by opioids, whose efficacy is overshadowed by the risks of addiction, tolerance, and dependence, culminating in the global opioid crisis. To transcend this issue, we must innovate beyond opioid-based μ receptor treatments, identifying nonopioid analgesics with high efficacy and minimal adverse effects. This Review navigates the multifaceted landscape of inflammatory, neuropathic, and nociplastic pain, emphasizing mechanism-based analgesic targets tailored to specific pain conditions. We delve into the challenges and breakthroughs in clinical trials targeting ion channels, GPCRs, and other molecular targets. We also highlight the intricate crosstalk between different physiological systems and the need for multimodal interventions with distinct pharmacodynamics to manage acute and chronic pain, respectively. Furthermore, we explore emerging strategies, including gene therapy, stem cell therapy, cell type-specific neuromodulation, and AI-driven techniques for objective, unbiased pain assessment and research. These innovative approaches are poised to revolutionize pain management, paving the way for the discovery of safer and more effective analgesics.

摘要

急性疼痛管理在历史上一直由阿片类药物主导,但其疗效因成瘾、耐受性和依赖性风险而黯然失色,最终导致了全球阿片类药物危机。为了克服这个问题,我们必须超越基于阿片类药物的μ受体治疗进行创新,寻找高效且副作用最小的非阿片类镇痛药。本综述探讨了炎症性疼痛、神经性疼痛和神经可塑性疼痛的多方面情况,强调针对特定疼痛状况的基于机制的镇痛靶点。我们深入研究了针对离子通道、G蛋白偶联受体(GPCR)和其他分子靶点的临床试验中的挑战与突破。我们还强调了不同生理系统之间复杂的相互作用,以及分别采用具有不同药效学的多模式干预措施来管理急性和慢性疼痛的必要性。此外,我们探索新兴策略,包括基因治疗、干细胞治疗、细胞类型特异性神经调节以及用于客观、无偏倚疼痛评估和研究的人工智能驱动技术。这些创新方法有望彻底改变疼痛管理,为发现更安全、更有效的镇痛药铺平道路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/12126239/7e6668efe4f7/jci-135-191346-g194.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验